GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

While inflation is the flavour of the day, deflation is a non-negligible risk too in a more normalised environment.

GlaxoSmithKline: Gem In Consumer Healthcare, Deflation Resistant, Keep Watch

Halozyme Therapeutics

Pfizer

LONDON and SAN DIEGO, June 22, 2021 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives exclusive access to Halozyme's ENHANZE® drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for specific targets used in the treatment and prevention of HIV.  Under the terms of the agreement, ViiV Healthcare will make an upfront payment of $40 million to Halozyme for the exclusive license to four HIV small and large molecule targets and is obligated to make potential future payments of up to $175 million in development and commercial milestones per target, subject to achievement of specified development and commercial milestones, including certain specified sales milestones.

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV

GlaxoSmithKline PLC ( GSK , Financial) investors are likely to find out this Wednesday just how much support Elliott Management can muster for the dramatic changes the activist investor is proposing for the British pharma giant. At Wednesday's meeting, beleaguered Glaxo CEO Emma Walmsley may be fighting to maintain her position as she reveals her plan for what is being called the “new GSK,” reported FiercePharma.

There Could Be Fireworks at Wednesday's Glaxo Investor Day

GlaxoSmithKline Plc's (NYSE: GSK) CEO Emma Walmsley struggled to win over key shareholders after Elliott Management attracted converts for radical change at the company, the Financial Times reported citing leading investors. Ahead of GSK's investor day on Wednesday (23 June), activist investor Elliott has sown doubt about whether Walmsley should stay to lead through the transformation planned after it spun off its consumer health division last year.

GlaxoSmithKline CEO Struggling To Get Key Shareholders In Her Favor Amid Pressure From Hedge Fund Activist Elliott Management

Vir Biotechnology

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating sotrovimab in high-risk adult outpatients with mild-to-moderate COVID-19. Data demonstrated a 79% reduction in hospitalization for more than 24 hours or death compared with placebo after 29 days.

GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients

The recent share price surge seen for GlaxoSmithKline PLC (LON:GSK) has probably saved Emma Walmsley's job but won't spare her from an uncomfortable Capital Markets Day this Wednesday. The chief executive, one of only seven women holding this role in the FTSE 100, is under close scrutiny by the City, with many people thinking she should have delivered more in the four years since her appointment.

GlaxoSmithKline share price surge keeps Emma Walmsley's head above water, but for how long?

GlaxoSmithKline will lay out plans to boost the spending power of its research-focused pharmaceuticals business at an investor day on Wednesday, as analysts call on the British drugmaker to boost drug development prospects with takeovers or alliances.

GSK to boost spending power of pharma business post break-up

Shares of Vir Biotechnology Inc. gained 1.4% in premarket trading on Monday after the company said the COVID-19 antibody treatment it developed with GlaxoSmithKline cut the risk of hospitalization and death among adults at high risk. The confirmatory data came from a Phase 3 clinical trial that was used to inform the emergency-use authorization granted to sotrovimab in late May.

Vir, GSK say new data confirms their COVID-19 treatment can reduce hospitalization and death

– Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces  hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk  of progression to severe disease –

GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab

Darden Restaurants

FedEx

Johnson & Johnson

NIKE

Equinix

CarMax

Paychex

Companies speaking with investors this week include Nike, FedEx, Johnson & Johnson, GlaxoSmithKline, and Darden Restaurants. Plus, PMIs, durable goods orders, and personal income and consumption.

Nike, FedEx, Johnson & Johnson, Darden, and Other Stocks to Watch This Week

The coming week is looking like a lighter one in terms of company news, however, there will be a few major names in the diary including blue-chip pharma firm GlaxoSmithKline and housebuilder Berkeley. Meanwhile, the macro calendar is set to be dominated by the latest decision on interest rates from the Bank of England following the Federal Reserve's meeting the previous week.

GlaxoSmithKline and Berkeley key names in coming week as Bank of England dominates macro dairy

iTeos Therapeutics, Inc.

Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.

Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug

GlaxoSmithKline PLC (LON:GSK) has “deep value” and the implied negative pipeline value is unwarranted, said a City broker. The pharma giant is hosting an investor event next week where management is expected to provide discussion about the growth outlook for the next five to ten years, confirm the extent of the proposed 2022 dividend cut and confirm the route and timing of the Consumer exit.

There's deep value in GlaxoSmithKline, says City broker

The biotech struck a potential $2 billion deal with a pharmaceutical giant.

Why iTeos Therapeutics Stock Soared Today

iTeos Therapeutics Inc (NASDAQ:ITOS) shares are trading higher by 36.7% at $27.38 Monday afternoon after the company and GlaxoSmithKline announced an agreement to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody. See Also: iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK

Why iTeos Therapeutics Shares Are Surging Today

Investors overwhelmed with dividend cut, spin off and no clarity on future strategy. GSK is moving towards the right direction.

GlaxoSmithKline: Relatively Undervalued - All Eyes On 23 June 2021

The stock price of iTeos Therapeutics Inc (NASDAQ: ITOS) increased by over 40% pre-market. These are the details.

ITOS Stock Price: Over 40% Increase Pre-Market Details

Shares of iTeos Therapeutics Inc. soared 58.5% in premarket trading on Monday after the company announced a deal with GlaxoSmithKline to develop and commercialize an experimental cancer therapy. GSK will make a $625 million upfront payment to iTeos, with an additional $1.4 billion in possible milestone payments available in the future.

iTeos stock jumps 60% after company announces deal with GSK

GlaxoSmithKline PLC (LON:GSK) has signed a US$2bn deal with US biotech Iteos Therapeutics (NASDQ:ITOS)  to strengthen its pharmaceutical division's cancer pipeline. The deal will see Glaxo pay US$625mln upfront and the remainder in royalty payments on sales outside of the US for a cancer-busting treatment under development by Iteos.

GlaxoSmithKline snaps up promising cancer treatment ahead of crunch investor day

(Reuters) -Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to iTeos Therapeutics Inc to develop and sell a potential cancer treatment together, the companies said on Monday.

GSK, iTeos to develop cancer drug in up to $2 billion deal

iTeos Therapeutics (NASDAQ: ITOS) and GlaxoSmithKline plc (NYSE: GSK) have agreed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody. Under the terms of the collaboration agreement, iTeos will receive an upfront payment of $625 million.

iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK

GOSSELIES, Belgium and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics (NASD: ITOS) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer. TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling preclinical data and a phase II randomised clinical trial. With this collaboration GSK is uniquely positioned with access to antibodies that synergistically target all three known CD226 checkpoints - TIGIT, CD96 and PVRIG.

iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations

Chevron

Gilead Sciences

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Exxon Mobil

According to the High Dividend Yield Screen, a Premium feature of GuruFocus, five stocks that have a dividend yield of at least 4% and at least 10 gurus buying shares as of June are Gilead Sciences Inc. ( GILD , Financial), Verizon Communications Inc. ( VZ , Financial), Exxon Mobil Corp. ( XOM , Financial), Chevron Corp. ( CVX , Financial) and GlaxoSmithKline PLC ( GSK , Financial).

5 High Dividend Yield Stocks Bought by Gurus as of June

GlaxoSmithKline plc (GSK) CEO Emma Walmsley Presents at CECP's Biopharma Investor Forum Conference (Transcript)

Merck

Viatris

Attractive dividends plus strong growth? Yes, please.

News for GlaxoSmithKline Stock (GSK)